MDx Firm Biocartis Raises $15M in Series A Round | GenomeWeb

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis has raised €10 million ($14.9 million) in a Series A financing round that included a handful of European investment firms.

The Lausanne, Switzerland-based firm is developing a multiplex, molecular diagnostics platform that will be able to quantify and amplify bio-analytes, such as proteins, nucleic acids, and small molecules. The firm said that it will use the proceeds from the private offering to develop a commercial version of its proprietary platform, as well as its first prototype assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.